{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:29:13Z","timestamp":1758475753873},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,4,19]],"date-time":"2012-04-19T00:00:00Z","timestamp":1334793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2012,11,15]]},"abstract":"Abstract<\/jats:title>Objectives<\/jats:bold><\/jats:title>Renal impairment (RI) is a predictor of poor outcomes in patients with cardiovascular disease, but its influence in the setting of percutaneous coronary intervention and zotarolimus\u2010eluting stent (ZES) implantation has not been described. This study evaluated the impact of RI on clinical outcomes in patients participating in the E\u2010Five Registry. Background: E\u2010Five was a prospective, multicenter, global registry of 8,314 patients; 2,116 patients were followed to 2 years.<\/jats:p><\/jats:sec>Methods<\/jats:title>Patients (excluding those who had undergone renal transplantation) were grouped according to renal function (normal function\/mild RI, serum creatinine <110 \u03bcmol\/L; moderate RI, 110\u2013200 \u03bcmol\/L; severe RI, >200 \u03bcmol\/L) and their outcomes evaluated retrospectively. Major adverse cardiac events (MACE; i.e., death, myocardial infarction, emergency cardiac bypass surgery, or target lesion revascularization) and stent thrombosis events at 1 and 2 years were compared between groups.<\/jats:p><\/jats:sec>Results<\/jats:title>The 1\u2010year MACE rate in patients with mild RI was 6.8%, compared with 8.9 and 18.1% in patients with moderate and severe RI (P<\/jats:italic> = 0.002 across groups). At 2 years, death occurred in 16% of those with severe RI, compared with 2.0 and 4.7% in those with mild and moderate RI (P<\/jats:italic> = 0.002). There was no significant difference in the rates of target lesion revascularization or target vessel failure.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Greater severity of RI at intervention is associated with greater mortality and MACE but unchanged revascularization rates after ZES implantation. \u00a9 2012 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ccd.23484","type":"journal-article","created":{"date-parts":[[2012,4,19]],"date-time":"2012-04-19T15:38:29Z","timestamp":1334849909000},"page":"885-892","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes in patients with renal impairment undergoing percutaneous coronary intervention and implantation of the Endeavor zotarolimus\u2010eluting stent: 1\u2010 and 2\u2010year data from the E\u2010Five Registry"],"prefix":"10.1002","volume":"80","author":[{"given":"Martin T.","family":"Rothman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the E\u2010Five Registry Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,19]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2008.06.012"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01745-X"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.04.013"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.108.828954"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2008.05.002"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.08.089"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2009.10.001"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.17.2038"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.04.001"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.01.032"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2011-300024"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.21016"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.191261"},{"volume-title":"USRDS 2009 annual data report: Atlas of end\u2010stage renal disease in the United States","year":"2009","author":"US Renal Data System","key":"e_1_2_7_17_2"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.23484","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.23484","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T20:55:34Z","timestamp":1700600134000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.23484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,19]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11,15]]}},"alternative-id":["10.1002\/ccd.23484"],"URL":"https:\/\/doi.org\/10.1002\/ccd.23484","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"type":"print","value":"1522-1946"},{"type":"electronic","value":"1522-726X"}],"subject":[],"published":{"date-parts":[[2012,4,19]]}}}